Indrayani Biotech Clarifies Share Volatility Amid Demerger, Rights Issue Discussions

Indrayani Biotech shares traded around ₹8.26 on April 2, 2026. The company reported significant financial strain, with total indebtedness of ₹54.48 crore as of January 31, 2026.

Company Response to Exchange Query

Indrayani Biotech Limited has formally responded to the BSE's query about its recent share price movements. The company attributes the volatility to market reactions following its announcements on April 6, 2026.

These announcements concerned upcoming Rights Issue Committee and Board meetings, both scheduled for April 9, 2026. The meetings will discuss a potential demerger of its food business and finalize terms for a partly paid-up rights issue.

The company emphasized that no undisclosed material information is currently affecting its share price or trading volume. The April 9th board meeting will specifically address the proposed food business demerger.

Investor Context

This clarification offers investors the company's view on recent stock activity, highlighting that price fluctuations are linked to forward-looking strategic plans rather than undisclosed problems.

The ongoing rights issue and demerger discussions are crucial for potential future value, especially considering the company's existing financial challenges.

Company Background and Financial Health

Indrayani Biotech, founded in 1992, operates a diversified portfolio spanning food & hospitality, biotech, and engineering.

In January 2026, the company faced significant financial challenges. It received a SARFAESI demand notice from Hinduja Leyland Finance due to loan defaults (classified as Non-Performing Assets or NPA) and reported total indebtedness of ₹54.48 crore.

The company's stock has experienced a significant decline over the past year. Despite these challenges, it is pursuing strategic growth opportunities such as a demerger and rights issue.

Impact for Shareholders

For shareholders, the clarification explains recent market action. The progress of the demerger and rights issue will be key factors in determining future shareholder value.

The company's ability to manage its current financial obligations alongside these new strategic initiatives will be vital for its recovery prospects.

Key Risks for Investors

• Significant financial distress, including existing loan defaults and NPA classification, remains a key concern.
• Execution risk for the proposed food business demerger and rights issue.
• Continued stock price volatility influenced by market sentiment and company performance.
• The company's ability to generate sustainable revenue and profits across its varied segments.

Industry Peers

Indrayani Biotech's diverse operations lead to comparisons with various industry players. In the broader food and agri-sector, notable peers include:

• Varun Beverages Ltd.: A market leader in its segment.
• Avanti Feeds Ltd.: A prominent player in animal feed and aquaculture.
• EID Parry (India) Ltd.: Involved in sugar, bio-products, and nutraceuticals.
• Sanstar Ltd.: Focused on castor oil derivatives and specialty chemicals, with agro-product segments.

These companies operate with different scales and business models, highlighting Indrayani Biotech's diversified but challenging operational environment.

Financial Snapshot

• Indrayani Biotech reported total financial indebtedness of ₹54.48 crore as of January 31, 2026.
• As of April 2, 2026, Indrayani Biotech's share price was ₹8.26.

Upcoming Milestones

• Outcomes of the April 9, 2026, Board Meeting on the food business demerger.
• Terms and progress of the partly paid-up Rights Issue, including size and price.
• Further disclosures on the company's financial health and debt servicing ability.
• Management commentary on the demerger's strategic rationale and execution plan.